ArticleFrontiers in medicine2020
Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review.Advances in therapy · 2026Pooled it
- Transitioning From Oral to Intravenous Treprostinil in Pulmonary Arterial Hypertension: A Case Report.Clinical case reports · 2026Article
- Transitioning Between Treprostinil Formulations: Evidence and Strategies.Advances in therapy · 2026Review
- Evaluation and Management of Sepsis in Pulmonary Hypertension.Journal of intensive care medicine · 2025Review
- Transitioning From Parenteral Prostanoids to Oral Selexipag in Pulmonary Arterial Hypertension: A Multicenter Retrospective Cohort Study.Pulmonary circulation · 2025Article
- Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration.Frontiers in pediatrics · 2023Article
- Hypertension in chronic kidney disease: What lies behind the scene.Frontiers in pharmacology · 2022Review
- Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension.Pulmonary circulation · 2022Article
- Real-world experience of selexipag titration in pulmonary arterial hypertension.The British journal of cardiology · 2021Article
- Management of Pulmonary Arterial Hypertension.Current cardiovascular risk reports · 2021Review
- Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.